RandomizEd controlled trial for pre-operAtive dose-escaLation BOOST in locally advanced rectal cancer (RECTAL BOOST study): Study protocol for a randomized controlled trial

Trials

Volumn 16, Issue 1, 2015, Pages

  Burbach, Maarten ^a   Verkooijen, Helena M ^a   Intven, Martijn ^a   Kleijnen, Jean Paul ^a   Bosman, Mirjam E ^a   Raaymakers, Bas W ^a   van Grevenstein, Wilhelmina ^a   Koopman, Miriam ^a   Seravalli, Enrica ^a   van Asselen, Bram ^a   Reerink, Onne ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE;

ADVANCED CANCER; ANASTOMOSIS LEAKAGE; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CHEMORADIOTHERAPY; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; FASCIA; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; INFORMED CONSENT; INTENSITY MODULATED RADIATION THERAPY; INTENTION TO TREAT ANALYSIS; LOCALLY ADVANCED RECTAL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PATHOLOGICAL COMPLETE RESPONSE; POSTOPERATIVE COMPLICATION; PREOPERATIVE CARE; PROSPECTIVE STUDY; QUALITY OF LIFE; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; RECTUM CANCER; TREATMENT RESPONSE; TUMOR LOCALIZATION; TUMOR VOLUME; CLINICAL PROTOCOL; METHODOLOGY; ORGANS AT RISK; PATHOLOGY; PSYCHOLOGY; RECTAL NEOPLASMS; SAMPLE SIZE; STATISTICAL ANALYSIS;

CHEMORADIOTHERAPY; CLINICAL PROTOCOLS; DATA INTERPRETATION, STATISTICAL; HUMANS; MAGNETIC RESONANCE IMAGING; ORGANS AT RISK; QUALITY OF LIFE; RECTAL NEOPLASMS; RESEARCH DESIGN; SAMPLE SIZE;

EID: 84924406162     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/s13063-015-0586-4     Document Type: Article

References (34)

1. International Agency for Research on Cancer, World Health Organization. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_population.aspx. Accessed 14 Feb 2015.
2. Netherlands Cancer Registry. Cancer statistics in the Netherlands. 2013. http://www.cijfersoverkanker.nl/. Accessed 14 Feb 2015.
3. Maas M, Nelemans PJ, Valentini V, Das P, Rödel C, Kuo LJ, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11:835-44.
4. Sanghera P, Wong DW, McConkey CC, Geh JI, Hartley A. Chemoradiotherapy for rectal cancer: an updated analysis of factors affecting pathological response. Clin Oncol (R Coll Radiol). 2008;20:176-83.
5. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma: clinicopathologic correlations. Cancer. 1994;73:2680-6.
6. Burbach JP, den Harder AM, Intven M, van Vulpen M, Verkooijen HM, Reerink O. Impact of radiotherapy boost on pathological complete response in patients with locally advanced rectal cancer: a systematic review and meta-analysis. Radiother Oncol. 2014;113:1-9.
7. Bökkerink GMJ, de Graaf EJ, Punt CJ, Nagtegaal ID, Rütten H, Nuyttens JJ, et al. The CARTS study: chemoradiation therapy for rectal cancer in the distal rectum followed by organ-sparing transanal endoscopic microsurgery. BMC Surg. 2011;11:34.
8. Pucciarelli S, De Paoli A, Guerrieri M, La Torre G, Maretto I, De Marchi F, et al. Local excision after preoperative chemoradiotherapy for rectal cancer: results of a multicenter phase II clinical trial. Dis Colon Rectum. 2013;56:1349-56.
9. ISRCTN Registry ISRCTN14422743. Transanal endoscopic microsurgery (TEM) and Radiotherapy in Early rectal Cancer: a randomised phase II feasibility study. http://www.controlled-trials.com/ISRCTN14422743/. Accessed 14 Feb 2015.
10. Maas M, Beets-Tan RG, Lambregts DM, Lammering G, Nelemans PJ, Engelen SM, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol. 2011;29:4633-40.
11. Smith JD, Ruby JA, Goodman KA, Saltz LB, Guillem JG, Weiser MR, et al. Nonoperative management of rectal cancer with complete clinical response after neoadjuvant therapy. Ann Surg. 2012;256:965-72.
12. Habr-Gama A, Gama-Rodrigues J, São Julião GP, Proscurshim I, Sabbagh C, Lynn PB, et al. Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control. Int J Radiat Oncol Biol Phys. 2014;88:822-8.
13. Agarwal A, Chang GJ, Hu CY, Taggart M, Rashid A, Park IJ, et al. Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy. Cancer. 2013;119:4231-41.
14. Martin ST, Heneghan HM, Winter DC. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br J Surg. 2012;99:918-28.
15. Zorcolo L, Rosman AS, Restivo A, Pisano M, Nigri GR, Fancellu A, et al. Complete pathologic response after combined modality treatment for rectal cancer and long-term survival: a meta-analysis. Ann Surg Oncol. 2012;19:2822-32.
16. ClinicalTrials.gov NCT02070146. The PICNIC Project: a ProspectIve Data CollectioN Initiative on Colorectal Cancer. http://clinicaltrials.gov/show/NCT02070146. Accessed 14 Feb 2015.
17. Relton C, Torgerson D, O'Cathain A, Nicholl J. Rethinking pragmatic randomised controlled trials: introducing the "cohort multiple randomised controlled trial" design. BMJ. 2010;340:c1066.
18. Sobin LH, Fleming ID. TNM Classification of malignant tumors. Fifth edition (1997). Union internationale contre le cancer and the American joint committee on cancer. Cancer. 1997;80:1803-4.
19. Dutch National Guidelines for Oncological Care: colorectal carcinoma. Version 3.0. Dutch. http://www.oncoline.nl/colorectaalcarcinoom. Accessed 14 Feb 2015.
20. Roels S, Duthoy W, Haustermans K, Penninckx F, Vandecaveye V, Boterberg T, et al. Definition and delineation of the clinical target volume for rectal cancer. Int J Radiat Oncol Biol Phys. 2006;65:1129-42.
21. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345:638-46.
22. Intven M, Reerink O, Philippens ME. Diffusion-weighted MRI in locally advanced rectal cancer: pathological response prediction after neo-adjuvant radiochemotherapy. Strahlenther Onkol. 2013;189:117-22.
23. Joiner M, Van der Kogel A. Basic clinical radiobiology. 4th ed. Boca Raton, FL: CRC Press; 2009.
24. Kleijnen JJE, Van Asselen B, Burbach JPM, Intven M, Reerink O, Lagendijk JJW, et al. MRI-based inter-fraction motion analysis for rectal cancer boost radiotherapy [abstract OC-0574]. In Proceedings of the European Society for Radiotherapy & Oncology: ESTRO 33; 4-8 Apr 2014; Vienna, Austria.
25. Quirke P, Morris E. Reporting colorectal cancer. Histopathology. 2007;50:103-12.
26. National Cancer Institute, National Institutes of Health. Common Terminology Criteria for Adverse Events (CTCAE) v.4 data files. http://evs.nci.nih.gov/ftp1/CTCAE/About.html] Accessed 14 Feb 2015.
27. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365-76.
28. Gujral S, Conroy T, Fleissner C, Sezer O, King PM, Avery KN, et al. Assessing quality of life in patients with colorectal cancer: an update of the EORTC quality of life questionnaire. Eur J Cancer. 2007;43:1564-73.
29. Whistance RN, Conroy T, Chie W, Costantini A, Sezer O, Koller M, et al. Clinical and psychometric validation of the EORTC QLQ-CR29 questionnaire module to assess health-related quality of life in patients with colorectal cancer. Eur J Cancer. 2009;45:3017-26.
30. Appelt AL, Ploen J, Vogelius IR, Bentzen SM, Jakobsen A. Radiation dose-response model for locally advanced rectal cancer after preoperative chemoradiation therapy. Int J Radiat Oncol Biol Phys. 2013;85:74-80.
31. Connell AM. Employing complier average causal effect analytic methods to examine effects of randomized encouragement trials. Am J Drug Alcohol Abuse. 2009;35:253-9.
32. Osoba D, Bezjak A, Brundage M, Zee B, Tu D, Pater J, et al. Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of the National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer. 2005;41:280-7.
33. ClinicalTrials.gov NCT01951521. RandomizEd Controlled Trial for Pre-operAtive Dose-escaLation BOOST in Locally Advanced Rectal Cancer (RECTAL BOOST study). http://clinicaltrials.gov/show/NCT01951521. Accessed 13 Feb 2015.
34. Gerard JP, Chapet O, Nemoz C, Hartweig J, Romestaing P, Coquard R, et al. Improved sphincter preservation in low rectal cancer with high-dose preoperative radiotherapy: the Lyon R96-02 randomized trial. J Clin Oncol. 2004;22:2404-9.